Topical Effects of Nebivolol on Wounds in Diabetic Rats

dc.contributor.author Gulcan, Erim
dc.contributor.author Kucuk, Aysegul
dc.contributor.author Cayci, Kasim
dc.contributor.author Tosun, Murat
dc.contributor.author Emre, Habib
dc.contributor.author Koral, Lokman
dc.contributor.author Avsar, Umit
dc.date.accessioned 2025-05-10T16:48:46Z
dc.date.available 2025-05-10T16:48:46Z
dc.date.issued 2012
dc.description Teksen, Yasemin/0000-0002-7224-3621; Kucuk, Aysegul/0000-0001-9316-9574 en_US
dc.description.abstract Objective: Recently, it has reported that nebivolol might be useful in the treatment of diabetes mellitus foot ulcers. The aim of this study was to examine treatment of the wounds in streptozotocin-induced diabetic rats with topical nebivolol. Methods: Two 15 x 15 mm-sized wounds were created in 56 streptozotocin-induced rats. A total of 56 diabetic wounds were studied in eight groups (n = 7). No treatment was administered to the first and second groups. The third and fourth groups consisted of diabetic rats that were administered 1:1 mixture of lanolin and vaseline for 7 and 14 days, respectively. Five percent nebivolol plus 1:1 mixture of lanolin and vaseline was administered to rats in the fifth and sixth groups for 7 and 14 days, respectively, and 10% nebivolol plus 1:1 mixture of lanolin and vaseline was administered to rats in the seventh and eighth groups for 7 and 14 days, respectively. On days 7 and 14, wound healing was observed, and the percent of wound healing was determined by measuring its size and histopathologic examination. The ratio was calculated by the formula, healing ratio (%) = 100 x (1-wound area/initial wound area). Statistical analysis was performed by ANOVA with Tukey's HSD test and Mann-Whitney U test, using SPSS 15.0 software. Results: On days 7 and 14, rates of wound healing in the fifth, sixth, seventh, and eighth groups were 57.42%, 89.16%, 60.80%, and 91.80%, respectively. Multiple comparison showed that rates of wound healing were significantly higher in rats administered 5% and 10% nebivolol than those in rats administered a mixture of lanolin and vaseline and in the untreated group (P < 0.05). Conclusion: Topical nebivolol therapy may be useful for wound healing in diabetic rats. Further studies are needed to support these data. (c) 2012 Elsevier B.V. All rights reserved. en_US
dc.identifier.doi 10.1016/j.ejps.2012.06.017
dc.identifier.issn 0928-0987
dc.identifier.uri https://doi.org/10.1016/j.ejps.2012.06.017
dc.identifier.uri https://hdl.handle.net/20.500.14720/1627
dc.language.iso en en_US
dc.publisher Elsevier Science Bv en_US
dc.rights info:eu-repo/semantics/closedAccess en_US
dc.subject Nebivol en_US
dc.subject Diabetic Wounds en_US
dc.subject Nitric Oxide en_US
dc.title Topical Effects of Nebivolol on Wounds in Diabetic Rats en_US
dc.type Article en_US
dspace.entity.type Publication
gdc.author.id Teksen, Yasemin/0000-0002-7224-3621
gdc.author.id Kucuk, Aysegul/0000-0001-9316-9574
gdc.author.wosid Küçük, Ayşegül/Afo-6819-2022
gdc.author.wosid Avşar, Ümit/Jmq-5616-2023
gdc.author.wosid Teksen, Yasemin/Jxy-1169-2024
gdc.coar.access metadata only access
gdc.coar.type text::journal::journal article
gdc.description.department T.C. Van Yüzüncü Yıl Üniversitesi en_US
gdc.description.departmenttemp [Gulcan, Erim; Avsar, Umit] Ataturk Univ, Fac Med, Dept Internal Med & Family Med, Erzurum, Turkey; [Tosun, Murat] Afyon Kocatepe Univ, Fac Med, Dept Histol & Embriol, Afyon, Turkey; [Emre, Habib] Yuzuncu Yil Univ, Fac Med, Dept Internal Med, Van, Turkey; [Koral, Lokman] Selcuk Univ, Fac Med, Dept Internal Med, Konya, Turkey; [Aktan, Yasemin] Dumlupinar Univ, Fac Med, Dept Pharmacol, Kutahya, Turkey en_US
gdc.description.endpage 455 en_US
gdc.description.issue 2 en_US
gdc.description.publicationcategory Makale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı en_US
gdc.description.scopusquality Q1
gdc.description.startpage 451 en_US
gdc.description.volume 47 en_US
gdc.description.woscitationindex Science Citation Index Expanded
gdc.description.wosquality Q2
gdc.identifier.pmid 22820030
gdc.identifier.wos WOS:000309029400019
gdc.index.type WoS
gdc.index.type PubMed

Files